Is an endocardial connection necessary for growth factor induced angiogenesis in transmyocardial laser revascularization?
Transmyocardial laser revascularization (TMLR) and therapeutic angiogenesis had emerged as potential tools in the treatment of angina refractory to conventional therapies. This combination might potentiate their effects, because angiogenesis is believed to be a basic mechanism in TMLR. The influence of channel connection with endocardial blood flow on angiogenesis is unclear. Twenty-five pigs (mean weight, 72.3 +/- 5 kg) were randomly assigned into five groups. In the transmural laser group, five transmyocardial channels were drilled. In the transmural mixed group, the same protocol was used followed by the injection of 100 microg of bovine bone derived growth factor mixture within each channel. The nontransmural laser group and the nontransmural mixed group underwent the same procedures, respectively, but the laser channels were drilled through the outer two-thirds of the myocardial wall. The control group had sham operations. Animals were allowed to survive for 1 month. Vascular densities were determined by computed morphometric analysis of histologic sections. Vascular counts of areas adjacent to the channels in the non- and transmural laser groups did not differ significantly from control groups (arteriolar counts: 0.27 +/- 0.16 and 0.26 +/- 0.16 vs. 0.29 +/- 0.11/mm2, respectively). When bovine bone protein growth factor mixture is added, neovascularization is increased significantly in non- and transmural mixed groups (1.04 +/- 0.79 and 0.69 +/- 0.37/mm2, respectively, p < 0.001 for both comparisons with corresponding laser groups), and there was no significant difference between mixed groups (p = 0.13). In this porcine model, the combination of TMLR with injection of bone protein growth factor mixture induced angiogenesis around the laser channels. Whether the channels did or did not communicate with the endocardial cavity did not influence the neovascular density.
Mueller
X M
XM
Clinic for Cardiovascular Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Tevaearai
H T
HT
Genton
C Y
CY
Chaubert
P
P
von Segesser
L K
LK
D000818:Animals; D001160:Arterioles / Q000502:physiology; D003324:Coronary Artery Disease / Q000628:therapy; D004699:Endocardium / Q000502:physiology*; D005169:Factor VIII / Q000032:analysis; D007335:Insulin-Like Growth Factor II; D007834:Lasers; D009204:Myocardial Revascularization / Q000379:methods*; D009206:Myocardium / Q000737:chemistry; D018919:Neovascularization, Physiologic / Q000187:drug effects / Q000502:physiology*; D011506:Proteins / Q000494:pharmacology*; D013552:Swine
C035170:IGF2 protein, human; D011506:Proteins; D007335:Insulin-Like Growth Factor II; D005169:Factor VIII